Eli Lilly & Co. (LLY) – Reuters
-
Lilly partners with Amazon to deliver Zepbound and other drugs
-
US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel
-
Novo valuation surpasses Tesla on experimental obesity drug data
-
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
-
Lilly rides wave of weight-loss drug demand, working to expand capacity
-
As Lilly rivalry flares, Novo CEO sets out Wegovy launch strategy
-
Weight loss drug windfall attracts pharma companies
-
US diabetes patients face delays as insurers tighten Ozempic coverage
-
Eli Lilly obesity drug now available in US pharmacies
-
Lilly's Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds
-
Lilly to build $2.5 billion Germany plant as obesity drug demand soars
-
Retail investors crowd into Eli Lilly after weight-loss drug approval
-
Eli Lilly extends tender offer to buy Point Biopharma after low participation
-
Eli Lilly to invest 2 billion euros to build first German production plant -source
-
Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy
-
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
-
Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist
-
U.S. employers covering weight-loss drugs could nearly double in 2024 - survey
-
Eli Lilly appoints new obesity unit head ahead of key Mounjaro decision
-
Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal
-
US judge overturns Eli Lilly's $176.5 million loss in Teva patent case
-
Lilly hits record high after Mounjaro fuels forecast raise, rival data
-
Lilly's obesity drug leads to about 26% weight loss in new studies
-
Experimental drug works best for Alzheimer's patients treated as early as possible
-
Eli Lilly to buy Versanis for up to $1.93 billion in obesity drugs push
-
Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
-
Eli Lilly raises annual profit forecast on strength of diabetes drug
-
Eli Lilly to invest additional $1.6 billion in 2 new plants
-
Lilly to cut some list prices by 70% and offer $25 insulin
-
Eli Lilly's weak diabetes drugs sales cloud 2023 profit forecast
-
Eli Lilly prepares for as many as 5 new drug launches next year
-
FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
-
Eli Lilly ordered to pay $176.5 million to Teva in U.S. migraine drug patent trial
-
Eli Lilly's dismal annual forecast overshadows quarterly beat
-
Eli Lilly's growth tied to nascent diabetes drug sales
-
Eli Lilly to buy gene therapy company Akouos for $487 million
-
Exclusive-U.S. finds new quality problems at Lilly drug factory
-
Analysis-Alzheimer's drug breakthrough big boost for Roche, Eli Lilly
-
Eli Lilly to supply additional doses of COVID antibody drug to U.S.
-
Eli Lilly obesity drug data shines, shares rise
-
U.S. FDA authorizes Eli Lilly's COVID-19 antibody drug
-
Eli Lilly pushes back timeline for Alzheimer's drug application
-
Experimental Lilly drug neutralizes Omicron in lab; slightly higher risk of diabetes seen in kids after COVID
-
Lilly sees 2022 profit above estimates on boost from potential new drugs
-
U.S. buys more doses of Lilly's COVID-19 treatment for $1.29 billion
-
Lilly kicks off application for Alzheimer's drug U.S. approval
-
Exclusive-Eli Lilly’s recalled emergency diabetes drug came from plant cited by FDA
-
FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus
-
Eli Lilly resolves lobbyist's sex discrimination lawsuit
-
Eli Lilly signs deals to boost supply of COVID-19 treatment in India
Back to LLY Stock Lookup
